Suche   Â
DGAP-News: Helix BioPharma Corp. Updates Shareholders on Results From Annual
General Meeting
ID: 563930
(firmenpresse) - Helix BioPharma Corp. / Key word(s): Miscellaneous
31.01.2012 03:06
---------------------------------------------------------------------------
AURORA, ON -- (Marketwire) -- 01/30/12 -- Helix BioPharma Corp.
(TSX: HBP) (NYSE Amex: HBP) (FRANKFURT: HBP) (the 'Company' or
'Helix') announces that its Annual General Meeting ('AGM' or the
'Meeting'), was held today as scheduled. The financial statements of
the Company were placed before the AGM and the auditors, KPMG LLP
Chartered Accountants, were reappointed.
The Chairman of the Meeting concluded that he had serious concerns
that shareholders had not been properly and fully informed in making
their voting decisions with respect to the election of directors and
that proxies have been solicited through misrepresentations. The
Chairman of the Meeting concluded that:
(a) There needs to be a new solicitation process and subsequent
shareholder vote with respect to the election of directors at a new
meeting of shareholders as soon as possible. The Company's former
European investor relations agent and affiliates should not be
involved in any part of this voting process or the new meeting and
shareholder solicitation.
(b) This new meeting should not be delayed unnecessarily and ought to
be called within 3 months at the latest.
(c) There should be no activities by the Company outside of the
ordinary course of business during this interim process prior to the
new meeting. The directors and management ought to act with fairness
through this interim period.
(d) The Board should be comprised of a 'coalition' until this matter
can be properly sorted out at a new and fair meeting.
The current board of directors will continue in their position until
the new meeting. During this interim period, on the recommendation of
the Chairman of the Meeting and subsequent approval of the current
Board, a formal invitation has been extended to two of the director
nominees of the dissident group offering them seats on the Board, one
of whom has also been invited to join the Special Committee. With the
addition of the two dissident group nominees, the Boards maximum
compliment of nine, pursuant to its constating documents, will be
reached.
The Company intends to apply to Court expeditiously in order to
proceed with the new meeting with a fair and transparent solicitation
process. In the interim, the Company intends to operate in the
ordinary course of business.
About Helix BioPharma Corp.
Helix BioPharma Corp. is a
biopharmaceutical company specializing in the field of cancer
therapy. The Company is actively developing innovative products for
the prevention and treatment of cancer based on its proprietary
technologies. Helix's product development initiatives include its
novel L-DOS47 new drug candidate and its Topical Interferon Alpha-
2b. Helix is listed on the TSX, NYSE Amex and FSE under the symbol
'HBP.'
Disclaimer and Forward-Looking Statements
This News Release
contains certain forward-looking statements and information
(collectively, 'forward-looking statements') within the meaning of
applicable securities laws. Forward-looking statements and
information are based on the beliefs, assumptions, opinions and
expectations of Helix's management at the time they are made. Readers
are cautioned not to place undue reliance on forward-looking
statements. The forward-looking statements contained herein are
expressly qualified by this cautionary statement and are made as of
the date of this News Release. Helix does not assume any obligation
to update any forward-looking statement or information should those
beliefs, assumptions, opinions or expectations, or other
circumstances change, except as required by law.
News Source: Marketwire
31.01.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Helix BioPharma Corp.
Canada
Phone:
Fax:
E-mail:
Internet:
ISIN: CA4229101098
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
  
  
  
Datum: 31.01.2012 - 03:06 Uhr
Sprache: Deutsch
News-ID 563930
Anzahl Zeichen: 5196
Kontakt-Informationen:
Kategorie:
Wirtschaft (allg.)
Diese Pressemitteilung wurde bisher 0 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Helix BioPharma Corp. Updates Shareholders on Results From Annual
General Meeting"
steht unter der journalistisch-redaktionellen Verantwortung von
Helix BioPharma Corp. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).